"The addition of Jnana's drug discovery technology and small molecule pipeline in PKU and autoimmune diseases will strengthen our R&D in the Boston area of the US, one of the most important ...

NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria WALNUT CREEK, ...

The first patient dosed with NGGT002 in the IIT trial showed a persistent plasma phenylalanine level within the normal range 40 weeks after the drug was dosed. Phase I/II clinical trials in the U.S.

(“Next Generation Gene Therapeutics” or “NGGT”), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced positive new data ...

Using drugs changes a person's brain structure and functioning, particularly in areas involved in reward, stress, and self-control. These alterations make it harder for people to stop using substances ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

Symptoms can range from acute (short-term) mania to depression and depressive episodes. Luckily, multiple treatments exist that can help you manage the condition. Medications such as mood stabilizers, ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

This organization has no public members. You must be a member to see who’s a part of this organization.

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement ...

Other examples include obesity, Gaucher's disease, phenylketonuria (PKU), medium-chain acyl-CoA dehydrogenase deficiency (MCADD), maple ... Have to maintain bodyweight, no alcohol and avoid smoking.